NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/moonlake-law ...

SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the clinical prospects of the company's lead and sole drug candidate, sonelokimab (SLK), causing the stock to crash nearly ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired MoonLake Immunotherapeutics common stock between March 10, 2024 through September 29, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Dec. 15, 2025 (GLOBE NEWSW ...

NEW YORK--(BUSINESS WIRE)---- $MLTX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Reuters Research Inc. ("MoonLake†or the "Company†) (NASDAQ: MLTX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. ...

San Francisco, California--(Newsfile Corp. - December 14, 2025) - Global plaintiffs' rights firm Hagens Berman reminds investors that the Lead Plaintiff Deadline in the securities class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) is rapidly approaching: December 15, 2025. The lawsuit alleges that MoonLake and certain executives made materially false and misleading statements regarding the clinical prospects of the company's lead and sole drug candidate, sonelokimab (SLK), causing the ...

NEW YORK, Dec. 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in MoonLake to Contact Him Directly to Discuss Their OptionsIf you purchased or acquired securities in MoonLake between March 10, 2024 and September 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information]New York, New York--(Newsfile Corp. - December 14 ...

诉讼事件概述 - 一家领先的证券律师事务所Bleichmar Fonti & Auld LLP宣布，已对MoonLake Immunotherapeutics及其部分高级执行官提起集体诉讼，指控其可能违反联邦证券法 [1] - 诉讼代表在纳斯达克交易MoonLake普通股的投资者提出，依据是《1934年证券交易法》第10(b)条和第20(a)条 [2] - 投资者申请担任首席原告的截止日期为2025年12月15日，案件正在美国纽约南区地方法院审理，案件编号为Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2] 公司业务与涉诉产品 - MoonLake是一家临床阶段的生物技术公司，专注于开发炎症性疾病疗法 [3] - 在相关期间，公司正在进行其研究性疗法sonelokimab针对中重度化脓性汗腺炎成人患者的高度期待的3期VELA临床试验 [3] - 公司向投资者宣传其“强大的临床数据”以及sonelokimab的纳米抗体结构优于竞争对手的传统单克隆抗体疗法，能带来更高的临床应答和差异化机会 [4] 指控核心与股价影响 - 指控称，公司的临床数据和纳米抗体结构并未带来优于竞争对手的临床效益，这令该药物获得监管批准和商业成功的可能性受到质疑 [5] - 2025年9月28日，公司公布了VELA 3期试验第16周的结果，其中VELA-2试验未能达到其主要终点，再次引发对药物前景的质疑 [6] - 此消息导致MoonLake股价从2025年9月26日的每股61.99美元暴跌至9月29日（下一个交易日）的每股6.24美元，下跌55.75美元，跌幅近90% [6]

诉讼核心信息 - 全球原告权利律师事务所Hagens Berman提醒投资者针对MoonLake Immunotherapeutics的证券集体诉讼中首席原告截止日期为2025年12月15日 [1] - 诉讼指控公司及其部分高管关于其主导且唯一的候选药物sonelokimab的临床前景做出了重大虚假和误导性陈述导致股价在披露令人失望的三期试验结果后暴跌近90% [2] - 诉讼核心指控为“纳米抗体欺骗”即公司反复声称SLK独特的纳米抗体结构将转化为相较于传统单克隆抗体疗法特别是已获FDA批准的竞争对手BIMZELX更优的临床疗效 [3] 诉讼具体指控与背景 - 公司向投资者反复保证其纳米抗体技术的所谓“优越性”而当VELA-2试验结果公布后这些承诺落空投资者几乎在一夜之间损失殆尽 [4] - 诉讼涉及的集体诉讼期间为2024年3月10日至2025年9月29日 [4] - 关键事件为2025年9月29日VELA-2试验未能达到其主要终点且疗效被证明劣于竞争对手后股价从61.99美元跌至6.24美元跌幅达90% [4] 涉事公司及药物 - 涉事公司为MoonLake Immunotherapeutics 股票代码为NASDAQ: MLTX [1][4] - 涉事的唯一主导候选药物为sonelokimab 简称SLK [2][3] - 被比较的竞争对手疗法是已获FDA批准的传统单克隆抗体药物BIMZELX [3] 投资者后续步骤 - 在2024年3月10日至2025年9月29日期间购买MoonLake股票并遭受重大损失的投资者被鼓励立即联系Hagens Berman讨论其法律选项及可能被任命为首席原告 [5] - 拥有MoonLake非公开信息的人士可考虑通过SEC举报人计划提供帮助提供原始信息的举报人可能获得SEC成功追回金额最高30%的奖励 [6] 律师事务所信息 - 代理此案的律师事务所Hagens Berman是一家专注于企业问责制的全球原告权利复杂诉讼事务所 [7] - 该事务所在此领域已为客户追回超过29亿美元 [7]

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In MoonLake (MLTX) To Contact Him Directly To Discuss Their Options If you purchased or acquired MoonLake Immunotherapeutics common stock between March 10, 2024 through September 29, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Dec. 13, 2025 (GLOBE NEWSW ...